[Federal Register Volume 76, Number 86 (Wednesday, May 4, 2011)]
[Notices]
[Pages 25357-25358]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-10813]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Advisory Committee; Medical Imaging Drugs Advisory Committee;
Reestablishment
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
[[Page 25358]]
reestablishment of the Medical Imaging Drugs Advisory Committee in the
Division of Advisory Committee and Consultants Management, Center for
Drug Evaluation and Research.
FOR FURTHER INFORMATION CONTACT: Minh Doan, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, rm. 2424, Silver Spring, MD 20993-0002, 301-796-9001, FAX:
301-847-8533, [email protected].
SUPPLEMENTARY INFORMATION: Under the Federal Advisory Committee Act of
October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app. 2)); section 904 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 394), as amended by the
Food and Drug Administration Revitalization Act (Pub. L. 101-635); and
21 CFR 14.40(b), FDA is announcing the reestablishment of the Medical
Imaging Drugs Advisory Committee by the Commissioner of Food and Drugs
(the Commissioner). A notice announcing a request for nominations for
members and representatives on the committee as well as a final rule
adding the committee to the current list of committees in 21 CFR 14.100
will be published at a later date.
The Medical Imaging Drugs Advisory Committee reviews and evaluates
data concerning the safety and effectiveness of marketed and
investigational human drug products for use in diagnostic and
therapeutic procedures using radioactive pharmaceuticals and contrast
media used in diagnostic radiology and makes appropriate
recommendations to the Commissioner.
The Medical Imaging Drugs Advisory Committee shall consist of a
core of 12 voting members including the chair. Members and the chair
are selected by the Commissioner or designee from among authorities
knowledgeable in the fields of nuclear medicine, radiology,
epidemiology or statistics, and related specialties. Almost all non-
Federal members of this committee serve as special Government
employees. The core of voting members may include one technically
qualified member, selected by the Commissioner or designee, who is
identified with consumer interests and is recommended by either a
consortium of consumer-oriented organizations or other interested
persons. In addition to the voting members, the committee may include
one nonvoting member who is identified with industry interests.
This notice is given under the Federal Advisory Committee Act and
21 CFR part 14, relating to advisory committees.
Dated: April 28, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-10813 Filed 5-3-11; 8:45 am]
BILLING CODE 4160-01-P